| Bioactivity | α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 can be used in studies of psychiatric disorders (such as schizophrenia, manic or hypomanic depression and anxiety disorders) and intellectual disorders (such as alzheimer's disease, learning deficits, cognitive deficits, attention deficits, memory loss, lewy body dementia and attention deficit hyperactivity disorder)[1]. |
| Target | α7 nAChR. |
| Name | α7 Nicotinic receptor agonist-1 |
| CAS | 220100-05-0 |
| Formula | C13H17N3O |
| Molar Mass | 231.29 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. James Loch Iii, et al. Novel aralkyl amines of spirofuropyridines useful in therapy. Patent WO2000042044A1. |
α7 Nicotinic receptor agonist-1
CAS: 220100-05-0 F: C13H17N3O W: 231.29
α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 can be used i
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.